Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cel-Sci Corp
(NY:
CVM
)
1.500
UNCHANGED
Official Closing Price
Updated: 6:30 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cel-Sci Corp
< Previous
1
2
3
Next >
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
March 19, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Issues Letter to Shareholders
March 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
February 15, 2024
From
CEL-SCI Corporation
Via
Business Wire
InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes on $7.75M Public Offering
February 14, 2024
Via
Investor Brand Network
Exposures
Product Safety
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
February 13, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
February 09, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
February 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
January 31, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
December 22, 2023
From
CEL-SCI Corporation
Via
Business Wire
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
December 04, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
November 20, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
November 16, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Issues Letter to Shareholders
October 30, 2023
From
CEL-SCI Corporation
Via
Business Wire
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
October 24, 2023
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
October 24, 2023
From
CEL-SCI Corporation
Via
Business Wire
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
October 23, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
October 19, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
October 05, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
September 26, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
August 11, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of Public Offering
July 20, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of Public Offering
July 17, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Proposed Public Offering of Common Stock
July 17, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer
July 14, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer
July 11, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed
June 22, 2023
From
CEL-SCI Corporation
Via
Business Wire
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
May 15, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
May 12, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
April 27, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
April 19, 2023
From
CEL-SCI Corporation
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.